Second quarter 2011 included $13.4 million of gain on Akorn-Strides LLC’s sale of its remaining abbreviated new medication approvals to Pfizer. Akorn-Strides LLC ceased operations during the quarter also. Second quarter 2011 results also included the acceleration of $1.4 million in amortization expense for deferred financing costs related to the early termination of the Company’s $10.0 million revolving credit agreement with EJ Funds LP along with $0.on June 1 6 million in incremental curiosity expenditure from the convertible debt issued. Related StoriesPatients offered animal-assisted therapy at UCLA HealthGlan Clwyd Hospital N Wales invest in Esaote's G-Scan MRI device for weight-bearing scanningLoyola Medicine, Palos Community Hospital launch innovative telemedicine programRaj Rai jointly, CEO commented, We’d another great quarter while both our ophthalmic and specialty injectable product lines continue steadily to show sequential development.For the 1st 24 weeks, the treatment assignments were double-blinded for sufferers in two of the three telaprevir organizations . At week 24, patients in the T12PR24 group and those in the T24P24 group ended treatment, and treatment continuing, through week 48, for sufferers in the T24PR48 group and those in the PR48 group. Sufferers randomly designated to retreatment with peginterferon alfa-2a and ribavirin who didn’t have got a sustained virologic response had been subsequently offered usage of telaprevir, peginterferon alfa-2a, and ribavirin, in a separate study. Efficacy Assessments Plasma HCV RNA amounts were measured by using the COBAS TaqMan HCV assay, version 1.0 , with a lower limit of quantification of 30 IU per milliliter and a lower limit of detection of 10 IU per milliliter.